 Jose Banchs
Concepts (254)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Echocardiography | 16 | 2021 | 558 | 3.610 |
Why?
| | Heart Diseases | 12 | 2022 | 330 | 2.500 |
Why?
| | Neoplasms | 22 | 2023 | 2118 | 2.420 |
Why?
| | Echocardiography, Transesophageal | 4 | 2019 | 89 | 1.220 |
Why?
| | Heart Ventricles | 7 | 2023 | 712 | 1.200 |
Why?
| | Ventricular Dysfunction, Left | 7 | 2022 | 366 | 1.190 |
Why?
| | Ventricular Function, Left | 7 | 2022 | 467 | 1.190 |
Why?
| | Cardiovascular Diseases | 8 | 2022 | 1724 | 1.040 |
Why?
| | Heart Neoplasms | 3 | 2018 | 50 | 1.000 |
Why?
| | Antineoplastic Agents | 10 | 2019 | 1893 | 0.990 |
Why?
| | Anthracyclines | 5 | 2022 | 41 | 0.980 |
Why?
| | Atrial Flutter | 1 | 2023 | 25 | 0.870 |
Why?
| | Atrial Fibrillation | 3 | 2023 | 325 | 0.850 |
Why?
| | Cardiovascular System | 2 | 2023 | 124 | 0.820 |
Why?
| | Stroke Volume | 7 | 2022 | 509 | 0.790 |
Why?
| | Sarcoma | 3 | 2023 | 137 | 0.770 |
Why?
| | Cardiology | 4 | 2020 | 260 | 0.770 |
Why?
| | Medical Oncology | 5 | 2020 | 230 | 0.740 |
Why?
| | Heart Function Tests | 2 | 2019 | 59 | 0.680 |
Why?
| | Practice Patterns, Nurses' | 1 | 2018 | 15 | 0.630 |
Why?
| | Osteosarcoma | 1 | 2019 | 66 | 0.620 |
Why?
| | Thrombosis | 2 | 2018 | 302 | 0.610 |
Why?
| | Endocarditis | 2 | 2021 | 32 | 0.590 |
Why?
| | Thrombocytopenia | 1 | 2019 | 175 | 0.580 |
Why?
| | Tachycardia, Sinus | 1 | 2016 | 1 | 0.570 |
Why?
| | Diagnostic Imaging | 3 | 2018 | 296 | 0.560 |
Why?
| | Cardiotoxicity | 8 | 2023 | 28 | 0.550 |
Why?
| | Pericardial Effusion | 4 | 2019 | 21 | 0.540 |
Why?
| | Echocardiography, Three-Dimensional | 2 | 2018 | 48 | 0.530 |
Why?
| | Cardiomyopathies | 2 | 2016 | 303 | 0.520 |
Why?
| | Education, Medical, Continuing | 1 | 2016 | 119 | 0.510 |
Why?
| | Recovery of Function | 2 | 2016 | 577 | 0.510 |
Why?
| | Takotsubo Cardiomyopathy | 1 | 2015 | 4 | 0.500 |
Why?
| | Rural Population | 1 | 2018 | 447 | 0.490 |
Why?
| | Pericarditis | 1 | 2014 | 9 | 0.490 |
Why?
| | Fibroma | 1 | 2014 | 21 | 0.480 |
Why?
| | Heart | 4 | 2023 | 608 | 0.470 |
Why?
| | Aortic Aneurysm | 1 | 2014 | 50 | 0.470 |
Why?
| | Radiotherapy | 1 | 2015 | 177 | 0.460 |
Why?
| | Breast Neoplasms | 7 | 2022 | 1872 | 0.450 |
Why?
| | Radiation Injuries | 1 | 2015 | 127 | 0.450 |
Why?
| | Humans | 60 | 2023 | 115587 | 0.440 |
Why?
| | Multimodal Imaging | 4 | 2018 | 98 | 0.420 |
Why?
| | Heart Valve Prosthesis Implantation | 1 | 2014 | 169 | 0.410 |
Why?
| | Cardiovascular Infections | 1 | 2012 | 2 | 0.410 |
Why?
| | Vascular Diseases | 1 | 2015 | 230 | 0.400 |
Why?
| | Tongue Neoplasms | 1 | 2012 | 20 | 0.400 |
Why?
| | Cardiac Tamponade | 3 | 2016 | 14 | 0.390 |
Why?
| | Mass Screening | 1 | 2018 | 1024 | 0.390 |
Why?
| | Tracheoesophageal Fistula | 1 | 2011 | 31 | 0.380 |
Why?
| | Myocarditis | 1 | 2012 | 94 | 0.380 |
Why?
| | Middle Aged | 23 | 2022 | 26999 | 0.380 |
Why?
| | Fluoroscopy | 1 | 2011 | 141 | 0.370 |
Why?
| | Radiography, Interventional | 1 | 2011 | 111 | 0.370 |
Why?
| | Ultrasonography, Interventional | 1 | 2011 | 125 | 0.370 |
Why?
| | Female | 32 | 2022 | 59913 | 0.340 |
Why?
| | Trastuzumab | 5 | 2016 | 89 | 0.340 |
Why?
| | Male | 28 | 2022 | 55949 | 0.330 |
Why?
| | Quality Improvement | 1 | 2016 | 958 | 0.330 |
Why?
| | Stents | 1 | 2011 | 475 | 0.300 |
Why?
| | Early Diagnosis | 3 | 2018 | 220 | 0.290 |
Why?
| | Coronary Artery Disease | 3 | 2021 | 607 | 0.290 |
Why?
| | Heart Failure | 4 | 2023 | 1963 | 0.290 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2012 | 577 | 0.280 |
Why?
| | Prognosis | 8 | 2023 | 3339 | 0.260 |
Why?
| | Risk Factors | 11 | 2023 | 8697 | 0.260 |
Why?
| | Echocardiography, Doppler, Color | 2 | 2015 | 37 | 0.250 |
Why?
| | Heart Conduction System | 2 | 2015 | 82 | 0.240 |
Why?
| | Predictive Value of Tests | 8 | 2022 | 1805 | 0.240 |
Why?
| | Troponin I | 3 | 2015 | 68 | 0.240 |
Why?
| | Esophageal Neoplasms | 2 | 2020 | 273 | 0.240 |
Why?
| | Retrospective Studies | 14 | 2022 | 12608 | 0.220 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 3 | 2019 | 1361 | 0.220 |
Why?
| | Circulating MicroRNA | 1 | 2023 | 24 | 0.220 |
Why?
| | Lung Neoplasms | 4 | 2020 | 2207 | 0.220 |
Why?
| | Texas | 4 | 2021 | 187 | 0.210 |
Why?
| | Fatal Outcome | 2 | 2015 | 286 | 0.210 |
Why?
| | Biomarkers | 7 | 2023 | 3466 | 0.210 |
Why?
| | Electrocardiography | 2 | 2015 | 560 | 0.200 |
Why?
| | Adult | 15 | 2022 | 30718 | 0.200 |
Why?
| | Mitogen-Activated Protein Kinase 7 | 1 | 2021 | 15 | 0.200 |
Why?
| | Ultrasonography | 3 | 2015 | 641 | 0.200 |
Why?
| | Doxorubicin | 3 | 2023 | 290 | 0.190 |
Why?
| | Poly(ADP-ribose) Polymerases | 1 | 2021 | 88 | 0.190 |
Why?
| | Catheters, Indwelling | 1 | 2021 | 79 | 0.190 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 1 | 2022 | 97 | 0.190 |
Why?
| | Aged | 12 | 2022 | 19251 | 0.180 |
Why?
| | Radiation, Ionizing | 1 | 2020 | 73 | 0.180 |
Why?
| | Ventricular Dysfunction, Right | 1 | 2023 | 222 | 0.180 |
Why?
| | Shock, Septic | 1 | 2021 | 185 | 0.170 |
Why?
| | Graft vs Host Disease | 1 | 2021 | 212 | 0.170 |
Why?
| | ROC Curve | 2 | 2021 | 451 | 0.170 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 2 | 2020 | 963 | 0.170 |
Why?
| | Radiotherapy, Intensity-Modulated | 1 | 2020 | 123 | 0.170 |
Why?
| | Pericardiocentesis | 1 | 2019 | 9 | 0.170 |
Why?
| | Erdheim-Chester Disease | 1 | 2018 | 5 | 0.160 |
Why?
| | Systole | 2 | 2016 | 169 | 0.160 |
Why?
| | Follow-Up Studies | 5 | 2021 | 4440 | 0.160 |
Why?
| | Cardiac Imaging Techniques | 1 | 2018 | 13 | 0.160 |
Why?
| | Myxoma | 1 | 2018 | 11 | 0.160 |
Why?
| | Echocardiography, Doppler | 1 | 2018 | 90 | 0.150 |
Why?
| | Staphylococcus aureus | 1 | 2021 | 385 | 0.150 |
Why?
| | Carcinoid Heart Disease | 1 | 2017 | 2 | 0.150 |
Why?
| | MicroRNAs | 1 | 2023 | 607 | 0.150 |
Why?
| | Staphylococcal Infections | 1 | 2021 | 337 | 0.140 |
Why?
| | Multiple Myeloma | 1 | 2018 | 93 | 0.140 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2019 | 154 | 0.140 |
Why?
| | Reproducibility of Results | 2 | 2016 | 2800 | 0.140 |
Why?
| | Academies and Institutes | 1 | 2016 | 44 | 0.140 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2021 | 519 | 0.140 |
Why?
| | Oligopeptides | 1 | 2018 | 248 | 0.140 |
Why?
| | Pericarditis, Constrictive | 1 | 2016 | 2 | 0.130 |
Why?
| | Myocardial Ischemia | 1 | 2018 | 237 | 0.130 |
Why?
| | Antibodies, Monoclonal, Humanized | 3 | 2015 | 667 | 0.130 |
Why?
| | Clinical Decision-Making | 1 | 2018 | 273 | 0.130 |
Why?
| | Withholding Treatment | 1 | 2016 | 69 | 0.130 |
Why?
| | Sepsis | 1 | 2021 | 515 | 0.130 |
Why?
| | Cardiotoxins | 1 | 2015 | 5 | 0.130 |
Why?
| | Cardiotonic Agents | 1 | 2016 | 119 | 0.130 |
Why?
| | Thrombolytic Therapy | 1 | 2016 | 118 | 0.130 |
Why?
| | Ventricular Dysfunction | 1 | 2015 | 16 | 0.120 |
Why?
| | Pulmonary Surgical Procedures | 1 | 2014 | 8 | 0.120 |
Why?
| | Daptomycin | 1 | 2014 | 17 | 0.120 |
Why?
| | Cefazolin | 1 | 2014 | 18 | 0.120 |
Why?
| | Comorbidity | 3 | 2019 | 1473 | 0.120 |
Why?
| | Pericardium | 1 | 2015 | 50 | 0.120 |
Why?
| | Carotid Artery Diseases | 1 | 2015 | 58 | 0.120 |
Why?
| | Dexmedetomidine | 1 | 2014 | 45 | 0.120 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2015 | 334 | 0.120 |
Why?
| | Postoperative Complications | 2 | 2015 | 2161 | 0.120 |
Why?
| | Survival Rate | 4 | 2021 | 1650 | 0.110 |
Why?
| | Pulmonary Embolism | 1 | 2016 | 182 | 0.110 |
Why?
| | Amyloidosis | 1 | 2014 | 36 | 0.110 |
Why?
| | Cardiopulmonary Resuscitation | 1 | 2016 | 220 | 0.110 |
Why?
| | Peroxidase | 1 | 2013 | 157 | 0.110 |
Why?
| | Myocardium | 1 | 2018 | 926 | 0.110 |
Why?
| | Chemoradiotherapy | 1 | 2014 | 187 | 0.110 |
Why?
| | Hodgkin Disease | 1 | 2015 | 118 | 0.110 |
Why?
| | Heart Valve Prosthesis | 1 | 2014 | 118 | 0.110 |
Why?
| | Coronary Vessels | 1 | 2015 | 229 | 0.110 |
Why?
| | Fluorodeoxyglucose F18 | 1 | 2013 | 125 | 0.110 |
Why?
| | Preoperative Care | 1 | 2015 | 318 | 0.100 |
Why?
| | Antibiotics, Antineoplastic | 2 | 2023 | 114 | 0.100 |
Why?
| | Decision Trees | 1 | 2012 | 81 | 0.100 |
Why?
| | Incidence | 4 | 2021 | 2335 | 0.100 |
Why?
| | Heart Arrest | 1 | 2016 | 289 | 0.100 |
Why?
| | Radiopharmaceuticals | 1 | 2013 | 187 | 0.100 |
Why?
| | Young Adult | 3 | 2019 | 10470 | 0.100 |
Why?
| | Positron-Emission Tomography | 1 | 2013 | 284 | 0.100 |
Why?
| | Hypertension, Pulmonary | 1 | 2023 | 1749 | 0.100 |
Why?
| | Antibiotic Prophylaxis | 1 | 2012 | 96 | 0.100 |
Why?
| | Endocarditis, Bacterial | 1 | 2012 | 36 | 0.100 |
Why?
| | Aortic Valve | 1 | 2014 | 342 | 0.090 |
Why?
| | Cardiac Catheterization | 1 | 2015 | 536 | 0.090 |
Why?
| | Radiosurgery | 1 | 2013 | 298 | 0.090 |
Why?
| | Prosthesis Implantation | 1 | 2011 | 139 | 0.090 |
Why?
| | Risk Assessment | 3 | 2018 | 2987 | 0.090 |
Why?
| | Combined Modality Therapy | 3 | 2018 | 1127 | 0.080 |
Why?
| | Anti-Inflammatory Agents | 1 | 2012 | 448 | 0.080 |
Why?
| | Myocardial Infarction | 1 | 2015 | 931 | 0.080 |
Why?
| | Treatment Outcome | 4 | 2018 | 9159 | 0.070 |
Why?
| | Animals | 5 | 2023 | 32102 | 0.070 |
Why?
| | Aged, 80 and over | 3 | 2015 | 6417 | 0.070 |
Why?
| | Sensitivity and Specificity | 1 | 2011 | 1718 | 0.070 |
Why?
| | Antiviral Agents | 1 | 2012 | 651 | 0.070 |
Why?
| | Palliative Care | 1 | 2012 | 642 | 0.060 |
Why?
| | Prevalence | 1 | 2011 | 2264 | 0.060 |
Why?
| | Troponin | 1 | 2023 | 44 | 0.060 |
Why?
| | Natriuretic Peptide, Brain | 2 | 2015 | 99 | 0.060 |
Why?
| | Adolescent | 2 | 2019 | 17889 | 0.050 |
Why?
| | Anti-Bacterial Agents | 1 | 2012 | 1484 | 0.050 |
Why?
| | Taxoids | 2 | 2013 | 94 | 0.050 |
Why?
| | Cell- and Tissue-Based Therapy | 1 | 2022 | 57 | 0.050 |
Why?
| | Antigens, CD19 | 1 | 2022 | 97 | 0.050 |
Why?
| | Ribose | 1 | 2021 | 17 | 0.050 |
Why?
| | Adenosine Diphosphate | 1 | 2021 | 81 | 0.050 |
Why?
| | Cyclophosphamide | 1 | 2021 | 218 | 0.050 |
Why?
| | Poly (ADP-Ribose) Polymerase-1 | 1 | 2021 | 40 | 0.050 |
Why?
| | Feedback | 1 | 2021 | 148 | 0.050 |
Why?
| | Ventricular Function, Right | 1 | 2023 | 251 | 0.050 |
Why?
| | Pulmonary Circulation | 1 | 2023 | 407 | 0.050 |
Why?
| | Tertiary Care Centers | 1 | 2021 | 127 | 0.050 |
Why?
| | United States | 4 | 2019 | 12295 | 0.050 |
Why?
| | Immunotherapy, Adoptive | 1 | 2022 | 194 | 0.040 |
Why?
| | Exercise Therapy | 1 | 2023 | 351 | 0.040 |
Why?
| | Poly-ADP-Ribose Binding Proteins | 1 | 2019 | 31 | 0.040 |
Why?
| | Radiotherapy Dosage | 1 | 2020 | 246 | 0.040 |
Why?
| | Peptide Fragments | 2 | 2015 | 675 | 0.040 |
Why?
| | DNA Topoisomerases, Type II | 1 | 2019 | 45 | 0.040 |
Why?
| | Immunocompromised Host | 1 | 2021 | 197 | 0.040 |
Why?
| | Multivariate Analysis | 2 | 2014 | 1440 | 0.040 |
Why?
| | Societies | 1 | 2018 | 39 | 0.040 |
Why?
| | Logistic Models | 2 | 2015 | 1856 | 0.040 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2022 | 630 | 0.040 |
Why?
| | Hemangiosarcoma | 1 | 2018 | 19 | 0.040 |
Why?
| | Positron Emission Tomography Computed Tomography | 1 | 2018 | 70 | 0.040 |
Why?
| | DNA Damage | 1 | 2020 | 357 | 0.040 |
Why?
| | Arterial Occlusive Diseases | 1 | 2018 | 73 | 0.040 |
Why?
| | Phosphorylation | 1 | 2021 | 1571 | 0.040 |
Why?
| | Reference Values | 1 | 2018 | 744 | 0.040 |
Why?
| | Prospective Studies | 2 | 2022 | 6264 | 0.040 |
Why?
| | Program Development | 1 | 2019 | 350 | 0.040 |
Why?
| | Molecular Targeted Therapy | 1 | 2019 | 348 | 0.040 |
Why?
| | Practice Guidelines as Topic | 2 | 2014 | 1405 | 0.040 |
Why?
| | Interprofessional Relations | 1 | 2019 | 258 | 0.030 |
Why?
| | Mice | 2 | 2023 | 15052 | 0.030 |
Why?
| | Morbidity | 1 | 2017 | 278 | 0.030 |
Why?
| | Mitochondria | 1 | 2021 | 750 | 0.030 |
Why?
| | Cytokines | 1 | 2023 | 1853 | 0.030 |
Why?
| | Galectin 3 | 1 | 2015 | 18 | 0.030 |
Why?
| | Recurrence | 1 | 2018 | 952 | 0.030 |
Why?
| | Growth Differentiation Factor 15 | 1 | 2015 | 34 | 0.030 |
Why?
| | Vascular Endothelial Growth Factor Receptor-1 | 1 | 2015 | 68 | 0.030 |
Why?
| | Global Health | 1 | 2017 | 290 | 0.030 |
Why?
| | Program Evaluation | 1 | 2019 | 836 | 0.030 |
Why?
| | Breast | 1 | 2015 | 138 | 0.030 |
Why?
| | Intraoperative Care | 1 | 2014 | 36 | 0.030 |
Why?
| | Biopsy | 1 | 2018 | 1056 | 0.030 |
Why?
| | Adrenergic alpha-2 Receptor Agonists | 1 | 2014 | 24 | 0.030 |
Why?
| | Diastole | 1 | 2015 | 134 | 0.030 |
Why?
| | Secondary Prevention | 1 | 2016 | 223 | 0.030 |
Why?
| | SEER Program | 1 | 2015 | 195 | 0.030 |
Why?
| | Oxidative Stress | 1 | 2020 | 1093 | 0.030 |
Why?
| | Drug Monitoring | 1 | 2015 | 184 | 0.030 |
Why?
| | Ohio | 1 | 2014 | 136 | 0.030 |
Why?
| | Clinical Trials, Phase I as Topic | 1 | 2014 | 46 | 0.030 |
Why?
| | Clinical Trials as Topic | 1 | 2018 | 941 | 0.030 |
Why?
| | Europe | 1 | 2014 | 336 | 0.030 |
Why?
| | Phenotype | 1 | 2021 | 2829 | 0.030 |
Why?
| | Acute Disease | 1 | 2016 | 914 | 0.030 |
Why?
| | C-Reactive Protein | 1 | 2015 | 364 | 0.030 |
Why?
| | Amyloid | 1 | 2014 | 82 | 0.030 |
Why?
| | Time Factors | 2 | 2013 | 6165 | 0.030 |
Why?
| | Anesthesia | 1 | 2014 | 119 | 0.030 |
Why?
| | Interleukin-1 Receptor-Like 1 Protein | 1 | 2012 | 22 | 0.030 |
Why?
| | Consensus | 1 | 2014 | 532 | 0.030 |
Why?
| | Odds Ratio | 1 | 2015 | 962 | 0.030 |
Why?
| | Action Potentials | 1 | 2015 | 410 | 0.020 |
Why?
| | Disease Management | 1 | 2016 | 563 | 0.020 |
Why?
| | Neoplasm Staging | 1 | 2015 | 1178 | 0.020 |
Why?
| | North America | 1 | 2012 | 261 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2014 | 815 | 0.020 |
Why?
| | Pilot Projects | 1 | 2016 | 1377 | 0.020 |
Why?
| | Radiology | 1 | 2014 | 196 | 0.020 |
Why?
| | Age Factors | 1 | 2018 | 2907 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2012 | 499 | 0.020 |
Why?
| | Myocardial Contraction | 1 | 2012 | 316 | 0.020 |
Why?
| | Societies, Medical | 1 | 2014 | 684 | 0.020 |
Why?
| | Receptors, Cell Surface | 1 | 2012 | 356 | 0.020 |
Why?
| | Patient Selection | 1 | 2014 | 654 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2015 | 2416 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2018 | 3069 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2015 | 4435 | 0.020 |
Why?
| | Cohort Studies | 1 | 2013 | 4944 | 0.010 |
Why?
|
|
Banchs's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|